Drug Safety Communications
FDA Drug Safety Communications connect consumers and health care professionals to important drug safety information.
The latest headlines across every section, pulled from official and open-access sources.
FDA Drug Safety Communications connect consumers and health care professionals to important drug safety information.
Information about incidents and outbreaks of Ebola and Marburg, both viral haemorrhagic fevers (VHF).
The company plans to eliminate 119 positions by mid-December as part of a phased transfer of some production from the manufacturing site.
The Food and Drug Administration (FDA) has approved changes to the Drugs Facts Label of the over-the-counter (OTC) weight loss drug, alli (orlistat) 60 mg capsules, to warn of risks of acute kidney injury, which is a rare side effect of the medication.
The next evolution of patient experience will not be defined by more digital touchpoints. It will be defined by giving nurses and care teams the capacity to be fully present. The post Restoring the Patient-Clinician Relationship to the Center of Care appeared first on MedCity News .
Prevention requires more than faster detection. Organizations need payment programs with end-to-end visibility and controls that intervene before losses occur. The post From Detection to Defense: Building Fraud-Resilient Healthcare Payment Systems appeared first on MedCity News .
[Sponsored] Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs. The post The Healthcare Payments Industry Has a Perception Problem appeared first on MedCity News .
Healthcare needs systems that work for providers, for health plans, and most importantly, for patients. And that starts with designing not just for technology, but for the people who depend on it, people who need to trust it will work when it matters most. The post Healthcare IT Isn’t Broken — But How We Design It Might Be appeared first on MedCity News .
Latest information on cases including British nationals.
Presence of foreign substance: small metallic particles in chewable tablets. — Guardian Drug Co. Inc. · Class II · Ongoing
Lack of Assurance of Sterility — Spectra Medical Devices, Llc · Class II · Ongoing
Presence of foreign substance: small metallic particles in chewable tablets. — Guardian Drug Co. Inc. · Class II · Ongoing
Presence of foreign substance: small metallic particles in chewable tablets. — Guardian Drug Co. Inc. · Class II · Ongoing
Presence of foreign substance: small metallic particles in chewable tablets. — Guardian Drug Co. Inc. · Class II · Ongoing
Labeling: Not Elsewhere Classified: The label wrap covers the barcode, making it hard to scan — Eugia US LLC · Class III · Ongoing
Presence of foreign substance: small metallic particles in chewable tablets. — Guardian Drug Co. Inc. · Class II · Ongoing
Presence of foreign substance: small metallic particles in chewable tablets. — Guardian Drug Co. Inc. · Class II · Ongoing
Presence of foreign substance: small metallic particles in chewable tablets. — Guardian Drug Co. Inc. · Class II · Ongoing
Presence of foreign substance: small metallic particles in chewable tablets. — Guardian Drug Co. Inc. · Class II · Ongoing
Presence of foreign substance: small metallic particles in chewable tablets. — Guardian Drug Co. Inc. · Class II · Ongoing
Presence of foreign substance: small metallic particles in chewable tablets. — Guardian Drug Co. Inc. · Class II · Ongoing
Presence of foreign substance: small metallic particles in chewable tablets. — Guardian Drug Co. Inc. · Class II · Ongoing
Presence of foreign substance: small metallic particles in chewable tablets. — Guardian Drug Co. Inc. · Class II · Ongoing
Presence of foreign substance: small metallic particles in chewable tablets. — Guardian Drug Co. Inc. · Class II · Ongoing